Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.

The international journal of neuropsychopharmacology - 15 Feb 2021

Kranzler Henry R, Lynch Kevin G, Crist Richard C, Hartwell Emily, Le Moigne Anne, Laffont Celine M, Andorn Anne C

Abstract excerpt

BACKGROUND: Buprenorphine treatment is not equally effective in all patients with opioid use disorder (OUD). Two retrospective studies showed that, among African Americans (AAs), rs678849, a polymorphism in the delta-opioid receptor gene, moderated the therapeutic effect of sublingual buprenorphine. METHODS: We examined rs678849 as a moderator of the response to an extended-release subcutaneous buprenorphine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Black or African American
Share to Delayed-Action Preparations
Share to Double-Blind Method
Share to Narcotics
Share to Opioid-Related Disorders
Share to Pharmacogenomic Testing
Share to Receptors, Opioid, delta
Share to White People

Source

Open in PubMed Open full text

Identifiers

PMID: 32920647
DOI: 10.1093/ijnp/pyaa069
PMCID: PMC7883889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.PMID 32920647Read ↗

An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.Semantic proximity Read ↗

Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females.Semantic proximity Read ↗

Association of OPRM1 Functional Coding Variant With Opioid Use DisorderSemantic proximity Read ↗

Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1.Semantic proximity Read ↗

Pharmacogenetics of Opioid Use Disorder Treatment.Semantic proximity Read ↗

A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder.Semantic proximity Read ↗

A review of the existing literature on buprenorphine pharmacogenomics.Semantic proximity Read ↗

Pharmacogenomics and Opioid Use Disorder: Clinical Decision Support in an African American Cohort.Semantic proximity Read ↗

OPRM1 rs2075572 has potential to affect plasma buprenorphine level in opioid users, but not OPRM1 rs562859.Semantic proximity Read ↗

Buprenorphine treatment of opioid dependence: analysis of individual patient dataSemantic proximity Read ↗

Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Semantic proximity Read ↗

A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.